首页> 外文期刊>The pharmaceutical journal >Discussing the MMR vaccine with patients
【24h】

Discussing the MMR vaccine with patients

机译:与患者讨论MMR疫苗

获取原文
获取原文并翻译 | 示例
           

摘要

As outlined in Public Health England's UK Measles and Rubella elimination strategy', MMR vaccination needs to improve to achieve and maintain elimination in line with recommendations from the World Health Organization. In 2017, the World Health Organization (WHO) announced that measles had been eliminated in the UK, owing to a "sustained interruption ol endemic transmission for at least 36 months"1. Despite this, measles remains a threat to the UK population, with sustained outbreaks occurring in both the UK and mainland Europe in 2018. More than half of the cases in Europe are in young people and adults who missed their measles, mumps and rubella (MMR) vaccines when they were younger2.
机译:如公共卫生英国的英国麻疹和风疹消除策略'所概述,MMR疫苗接种需要改进,以实现和维持世界卫生组织的建议。 2017年,世界卫生组织(世卫组织)宣布,由于“至少36个月的持续中断OL流行传播”1,这是英国被淘汰的麻疹。 尽管如此,麻疹仍然是对英国人口的威胁,2018年英国和大陆欧洲发生的持续爆发。欧洲的一半以上的案件都在错过了闷闷不乐,腮腺炎和风疹的年轻人和成年人(MMR )当他们是年轻人的疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号